Sage Journals: Discover world-class research

Abstract

Access to antiretroviral therapy is increasing globally and drug resistance evolution is anticipated. Currently, protease (PR) and reverse transcriptase (RT) sequence generation is increasing, including the use of in-house sequencing assays, and quality assessment prior to sequence analysis is essential. We created a computational HIV PR/RT Sequence Quality Analysis Tool (SQUAT) that runs in the R statistical environment. Sequence quality thresholds are calculated from a large dataset (46,802 PR and 44,432 RT sequences) from the published literature (http://hivdb.Stanford.edu). Nucleic acid sequences are read into SQUAT, identified, aligned, and translated. Nucleic acid sequences are flagged if with >five 1–2-base insertions; >one 3-base insertion; >one deletion; >six PR or >18 RT ambiguous bases; >three consecutive PR or >four RT nucleic acid mutations; >zero stop codons; >three PR or >six RT ambiguous amino acids; >three consecutive PR or >four RT amino acid mutations; >zero unique amino acids; or <0.5% or >15% genetic distance from another submitted sequence. Thresholds are user modifiable. SQUAT output includes a summary report with detailed comments for troubleshooting of flagged sequences, histograms of pairwise genetic distances, neighbor joining phylogenetic trees, and aligned nucleic and amino acid sequences. SQUAT is a stand-alone, free, web-independent tool to ensure use of high-quality HIV PR/RT sequences in interpretation and reporting of drug resistance, while increasing awareness and expertise and facilitating troubleshooting of potentially problematic sequences.

Get full access to this article

View all access options for this article.

References

Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS epidemic update. 2007. http://www.unaids.org/en/HIV_data/2007EpiUpdate/default.asp.

Palella

Jr , Delaney

, Moorman

et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med, 1998; 338,13:853–860.

Hirsch

, Gunthard

, Schapiro

et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis, 2008; 47,2:266–285.

DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents––A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. http://www.aidsinfo.nih.gov/guidelines.

Richman

, Morton

, Wrin

et al. The prevalence of antiretroviral drug resistance in the United States. AIDS, 2004; 18,10:1393–1401.

Little

, Holte

, Routy

et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med, 2002; 347,6:385–394.

McCutchan

. Global epidemiology of HIV. J Med Virol, 2006; 78,Suppl 1:S7–S12.

Hemelaar

, Gouws

, Ghys

, Osmanov

. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS, 2006; 20,16:W13–23.

Kantor

. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis, 2006; 19,6:594–606.

10.

Kantor

, Katzenstein

, Efron

et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotypic evolution: Results of a global collaboration. PLOS Med, 2005; 2:e112.

11.

Brenner

, Turner

, Oliveira

et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS, 2003; 17,1:F1–5.

12.

Brenner

, Oliveira

, Doualla-Bell

et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS, 2006; 20,9:F9–F13.

13.

Grossman

, Sugarman

, Auerbuch

et al. Reverse transcriptase T69 6-bo insertion and multi-class resistance within a population of nucleoside reverse transcriptase inhibitor-treated subtype C patients. Antivir Ther, 2002; 7,Suppl 1:S194.

14.

Saravanan

, Vidya

, Balakrishanan

et al. Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. J Virol Methods, 2009; 159,2:211–216.

15.

U.S. Food and Drug Administration. FDA licensed and approved HIV tests. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3982b1_Licensed-Approved%20HIV%20Tests.doc.

16.

Land

, Cunningham

, Zhou

et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods, 2009; 159,2:185–193.

17.

Galli

, Sattha

, Wynhoven

et al. Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance. J Clin Microbiol, 2003; 41,7:2900–2907.

18.

Huang

, Eshleman

, Brambilla

et al. Evaluation of the editing process in human immunodeficiency virus type 1 genotyping. J Clin Microbiol, 2003; 41,7:3265–3272.

19.

Gene Codes Corporation. Sequencher 4.10.1. DNA Sequence Assembly Software: For Mac and Windows.

20.

Ewing

, Hillier

, Wendl

, Green

. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res, 1998; 8,3:175–185.

21.

Korber

, Myers

. Signature pattern analysis: A method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses, 1992; 8:1549–1560.

22.

Boeri

, Canducci

, Grasso

et al. Phylogenetic internal control for HIV-1 genotypic antiretroviral testing. New Microbiol, 2004; 27,2 Suppl 1:105–109.

23.

Learn

Jr , Korber

, Foley

et al. Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol, 1996; 70:5720–5730.

24.

Kjaer

, Ledergerber

. HIV cohort collaborations: Proposal for harmonization of data exchange. Antivir Ther, 2004; 9,4:631–633.

25.

Larkin

, Blackshields

, Brown

et al. Clustal W and Clustal X version 2.0. Bioinformatics, 2007; 23,21:2947–2948.

26.

Edgar

. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res, 2004; 32,5:1792–1797.

27.

Korber

. HIV signature, sequence variation analysis. Computational and Evolutionary Analysis of HIV Molecular Sequences. Rodrigo

, Learn

. Kluwer Academic Publishers, Dordrecht: The Netherlands, 2000; 55–72.

28.

Los Alamos HIV Database. www.hiv.lanl.gov http://www.hiv.lanl.gov/content/index.

29.

Liu

, Shafer

. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis, 2006; 42,11:1608–1618.

30.

Sturmer

, Doerr

, Preiser

. Variety of interpretation systems for human immunodeficiency virus type 1 genotyping: Confirmatory information or additional confusion? Curr Drug Targets Infect Disord, 2003; 3,4:373–382.

31.

Kantor

, Machekano

, Gonzales

et al. Human immunodeficiency virus reverse transcriptase and protease sequence database: An expanded model integrating natural language text and sequence analysis. Nucleic Acids Res, 2001; 29:296–299.

32.

Rhee

, Gonzales

, Kantor

et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res, 2003; 31,1:298–303.

33.

Shafer

, Jung

, Betts

. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat Med, 2000; 6,11:1290–1292.

34.

Shafer

, Jung

, Betts

et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res, 2000; 28:346–348.

35.

Shafer

, Stevenson

, Chan

. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res, 1999; 27:348–352.

36.

R: A language and environment for statistical computing [computer program]. Version. Vienna, Austria http://www.R-project.org 2009.

37.

Perl. Programming language. http://www.perl.org/.

38.

Gonzales

, Dugan

, Shafer

. Synonymous-non-synonymous mutation rates between sequences containing ambiguous nucleotides (Syn-SCAN) Bioinformatics, 2002; 18,6:886–887.

39.

Paradis

, Claude

, Strimmer

. APE: Analyses of Phylogenetics and Evolution in R language. Bioinformatics, 2004; 20,2:289–290.

40.

FASTA. Sequence Format. http://www.ncbi.nlm.nih.gov/BLAST/fasta.shtml.

41.

Huang

, Zhang

. Methods for comparing a DNA sequence with a protein sequence. Comput Appl Biosci, 1996; 12,6:497–506.

42.

Johnson

, Brun-Vezinet

, Clotet

et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med, 2009; 17,5:138–145.

43.

Bennett

, Bertagnolio

, Sutherland

, Gilks

. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther, 2008; 13,Suppl 2:1–13.

44.

Bennett

, Myatt

, Bertagnolio

et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther, 2008; 13,Suppl 2:25–36.

45.

Jordan

, Bennett

, Bertagnolio

et al. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther, 2008; 13,Suppl 2:15–23.

46.

Genbank. http://www.ncbi.nlm.nih.gov/.

47.

Hughes

, Robinson

, Tseng

, MacArthur

. New antiretroviral drugs: A review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother, 2009; 10,15:2445–2466.

48.

Bhattacharya

, Osman

. Novel targets for anti-retroviral therapy. J Infect, 2009; 59,6:377–386.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.02 MB

0.00 MB

Sequence Quality Analysis Tool for HIV Type 1 Protease and Reverse Transcriptase

Abstract

Get full access to this article

References

Supplementary Material